CN112791063A - Carrier for removing inflammatory factors in joint cavity hydrops and releasing anti-inflammatory drugs - Google Patents
Carrier for removing inflammatory factors in joint cavity hydrops and releasing anti-inflammatory drugs Download PDFInfo
- Publication number
- CN112791063A CN112791063A CN202110067765.7A CN202110067765A CN112791063A CN 112791063 A CN112791063 A CN 112791063A CN 202110067765 A CN202110067765 A CN 202110067765A CN 112791063 A CN112791063 A CN 112791063A
- Authority
- CN
- China
- Prior art keywords
- inflammatory
- joint cavity
- vehicle
- spherical outer
- inflammatory factors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a carrier for removing inflammatory factors in joint cavity hydrops and releasing anti-inflammatory drugs, which comprises: the main structure comprises a spherical outer wrapping layer and a central sphere, wherein the spherical outer wrapping layer is evenly provided with a plurality of through holes, the central sphere wraps the inside of the spherical outer wrapping layer, the spherical outer wrapping layer is formed by a membrane made of phospholipid, the thickness of the spherical outer wrapping layer is 50-100um, the through holes are all round through holes, the aperture of each through hole is 30-50 um, and the central sphere is made of nanoscale anti-inflammatory drug particles. The carrier for removing the inflammatory factors in the joint cavity hydrops and releasing the anti-inflammatory drugs provided by the invention can be metabolized and absorbed by a human body, not only can effectively remove the inflammatory factors in the joint cavity of the human body, but also can be released as the carrier to slowly release the anti-inflammatory drugs, and finally, the purpose of removing the inflammatory factors in the joint cavity and controlling local inflammation is achieved, and the purpose of controlling the state of an illness is achieved, and no side effect is caused.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a carrier for removing inflammatory factors in joint cavity hydrops and releasing anti-inflammatory drugs.
Background
Due to some disease factors (such as RA, osteoarthritis and trauma), the local joint cavity effusion of a patient can occur, particularly the knee joint, the joint cavity effusion of most patients is large, and the joint cavity effusion contains a plurality of inflammatory factors, so that the local inflammation aggravates or the joint is damaged after the long-term existence. Clinically, joint intra-cavity effusion is extracted and intra-cavity injection medicines are mostly adopted to treat patients, the intra-cavity injection medicines are generally hormones (diprospan), lubricants (sodium hyaluronate), TNF-alpha antagonists and the like, but the hormones, the lubricants, the TNF-alpha antagonists and the like used in the joint intra-cavity effusion are not absorbed by human metabolism, so that not only are the inflammatory factors in the joint intra-cavity of the human body difficult to clear, but also the local inflammation is difficult to control, the side effect is great, and finally the condition of the patients is difficult to control.
Therefore, a carrier for removing inflammatory factors in joint cavity hydrops and releasing anti-inflammatory drugs is provided.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide a carrier for removing inflammatory factors in joint cavity hydrops and releasing anti-inflammatory drugs, which can be metabolized and absorbed by a human body, can effectively remove the inflammatory factors in the joint cavity of the human body, can be released as the carrier to slowly release the anti-inflammatory drugs, finally achieves the purposes of removing the inflammatory factors in the joint cavity and controlling local inflammation so as to control the state of an illness, has no side effect and solves the problems in the background art.
In order to achieve the purpose, the invention provides the following technical scheme:
a carrier for removing inflammatory factors from joint cavity fluid and releasing an anti-inflammatory agent, comprising:
the main part structure, the main part structure includes spherical outer parcel layer and central spheroid, evenly be equipped with a plurality of through-holes on the spherical outer parcel layer, central spheroid parcel is in the inside on spherical outer parcel layer.
By adopting the technical scheme, the designed carrier for removing the inflammatory factors in the joint cavity effusion and releasing the anti-inflammatory drugs is composed of the spherical outer wrapping layer and the central sphere, is spherical in shape, and is reasonable in design, convenient to inject into the joint cavity to remove the inflammatory factors in the joint cavity effusion, and capable of effectively improving the speed of removing the inflammatory factors in the joint cavity effusion by the carrier, and meanwhile, the concentration of the anti-inflammatory drugs released by the carrier is balanced, so that the effect of removing the inflammatory factors in the joint cavity effusion by the carrier is ensured.
Further, the spherical outer coating layer is formed by a membrane made of phospholipid.
By adopting the technical scheme, the spherical outer wrapping layer formed by the membrane made of phospholipid can be finally metabolized and absorbed by human body, and the safety is higher.
Further, the thickness of the spherical outer wrapping layer is 50-100 um.
By adopting the technical scheme, the strength of the spherical outer wrapping layer can be ensured, the spherical outer wrapping layer is not easy to break, and the time of the spherical outer wrapping layer in a human body can be ensured so as to ensure that the central sphere can be uniformly released into joint cavity effusion.
Furthermore, the through holes are all round through holes.
Through adopting above-mentioned technical scheme, all set up the through-hole into circular through-hole, can guarantee that the edge of through-hole is difficult to be torn to guarantee this carrier structure relatively stable, can stably release anti-inflammatory drug.
Furthermore, the aperture of each through hole is 30um-50 um.
Through adopting above-mentioned technical scheme, all set up the aperture of through-hole to 30um-50um, can guarantee the trafficability characteristic of through-hole, can guarantee the speed that the anti-inflammatory drug that releases passes through the through-hole again.
Further, the central sphere is made of nano-sized anti-inflammatory drug particles.
By adopting the technical scheme, the central sphere can release anti-inflammatory drugs.
Furthermore, the particle size of the anti-inflammatory drug particles is 50-80 nm.
By adopting the technical scheme, the anti-inflammatory drug can be fully combined with the inflammatory factors in the joint cavity, and the purpose of thoroughly removing the inflammatory factors is achieved.
Further, the outer diameter of the spherical outer wrapping layer is 300-500 um.
By adopting the technical scheme, the carrier is small and exquisite in whole, and foreign body sensation generated by a patient when the carrier is injected into a joint cavity is avoided.
Further, the anti-inflammatory drug comprises one or more of aspirin, acetaminophen, indomethacin, naproxen, naproxone, diclofenac, ibuprofen, nimesulide, rofecoxib, and celecoxib.
By adopting the technical scheme, the anti-inflammatory drug can be well absorbed by the internal tissues of the joints of the human body, so that the effect of treating arthritis is ensured.
Further, the phospholipid is phosphoglyceride or sphingomyelin, and the phosphoglyceride is lecithin or cephalin or cardiolipin.
By adopting the technical scheme, the phospholipid prepared from the phosphoglyceride or the sphingomyelin is easy to be metabolized and absorbed by human bodies, and has better safety.
In summary, the invention mainly has the following beneficial effects:
the carrier for removing the inflammatory factors in the joint cavity hydrops and releasing the anti-inflammatory drugs comprises the spherical outer wrapping layer and the central sphere, is spherical as a whole, is reasonable in design, is convenient to inject into the joint cavity to remove the inflammatory factors in the joint cavity hydrops, maximizes the surface area of the carrier, can effectively improve the speed of removing the inflammatory factors in the joint cavity hydrops by the carrier, balances the concentration of the anti-inflammatory drugs released by the carrier, further ensures the effect of removing the inflammatory factors in the joint cavity hydrops by the carrier, can be metabolized and absorbed by a human body finally, is high in safety, and can release the anti-inflammatory drugs, and the central sphere is made of nanoscale anti-inflammatory drug particles;
therefore, the carrier for removing the inflammatory factors in the joint cavity hydrops and releasing the anti-inflammatory drugs can be metabolized and absorbed by a human body, not only can effectively remove the inflammatory factors in the joint cavity of the human body, but also can be released as the carrier to slowly release the anti-inflammatory drugs, finally achieves the purposes of removing the inflammatory factors in the joint cavity and controlling local inflammation so as to achieve the purpose of controlling the state of an illness, and has no side effect.
Drawings
FIG. 1 is a schematic perspective view of one embodiment of a vehicle for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity fluid;
FIG. 2 is a schematic diagram of a planar structure of an embodiment of a carrier for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity effusion;
FIG. 3 is a schematic cross-sectional view along section line A-A of one embodiment of a vehicle for removing inflammatory factors and releasing anti-inflammatory agents from joint cavity fluid;
FIG. 4 is a schematic diagram of a semi-sectional structure of one embodiment of a carrier for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity effusion.
In the figure: 1. a spherical outer wrapping layer; 2. a central sphere; 3. and a through hole.
Detailed Description
The invention is described in further detail below with reference to figures 1-4.
Example 1
A carrier for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity effusion, as shown in fig. 1-4, comprising:
the main part structure, main part structure include spherical outer parcel layer 1 and central spheroid 2, evenly are equipped with a plurality of through-holes 3 on the spherical outer parcel layer 1, and central spheroid 2 wraps up the inside at spherical outer parcel layer 1.
The carrier for clearing away the inflammatory factors in the joint cavity hydrops and releasing the anti-inflammatory drugs is composed of the spherical outer wrapping layer 1 and the central sphere 2, is spherical in shape, is reasonable in design, is convenient to inject into the joint cavity to clear away the inflammatory factors in the joint cavity hydrops, maximizes the surface area of the carrier, can effectively improve the speed of clearing away the inflammatory factors in the joint cavity hydrops by the carrier, balances the concentration of the anti-inflammatory drugs released by the carrier, and further ensures the effect of clearing away the inflammatory factors in the joint cavity hydrops by the carrier.
Specifically, the spherical outer wrapping layer 1 is formed by a membrane made of phospholipid, and the spherical outer wrapping layer 1 formed by the membrane made of phospholipid can be finally metabolized and absorbed by human bodies, so that the safety is high.
Specifically, the thickness of the spherical outer wrapping layer 1 is 50-100um, so that the strength of the spherical outer wrapping layer 1 can be ensured, the spherical outer wrapping layer is not easy to break, the time of the spherical outer wrapping layer 1 remaining in a human body can be ensured, and the central sphere 2 can be uniformly released into joint cavity effusion.
Specifically, a plurality of through-holes 3 are circular through-holes, all set up through-holes 3 into circular through-holes, can guarantee that the edge of through-hole 3 is difficult to be torn to guarantee that this carrier structure is more stable, can stably release anti-inflammatory drug.
Specifically, the aperture of a plurality of through holes 3 is 30um-50um, and the aperture of the through holes 3 is set to be 30um-50um, so that the passing ability of the through holes 3 can be ensured, and the speed of the released anti-inflammatory drugs passing through the through holes 3 can be ensured.
Specifically, the central sphere 2 is made of nano-sized anti-inflammatory drug particles, so that the central sphere 2 can release the anti-inflammatory drug.
Specifically, the particle size of the anti-inflammatory drug particles is 50-80nm, so that the anti-inflammatory drug can be fully combined with inflammatory factors in joint cavities, and the purpose of thoroughly removing the inflammatory factors is achieved.
Specifically, the outer diameter of the spherical outer wrapping layer 1 is 300-.
Specifically, the anti-inflammatory drug comprises one or more of aspirin, acetaminophen, indomethacin, naproxen, naproxone, diclofenac, ibuprofen, nimesulide, rofecoxib and celecoxib, so that the anti-inflammatory drug can be well absorbed by internal tissues of joints of a human body, and the effect of treating arthritis is guaranteed.
Specifically, the phospholipid is phosphoglyceride or sphingomyelin, the phosphoglyceride is lecithin or cephalin or cardiolipin, and the phospholipid prepared from the phosphoglyceride or the sphingomyelin is easy to be metabolized and absorbed by a human body and has better safety.
In conclusion, the carrier for removing the inflammatory factors in the joint cavity hydrops and releasing the anti-inflammatory drugs comprises the spherical outer wrapping layer 1 and the central sphere 2, is spherical as a whole, is reasonable in design, is convenient to inject into the joint cavity to remove the inflammatory factors in the joint cavity hydrops, maximizes the surface area of the carrier, can effectively improve the speed of removing the inflammatory factors in the joint cavity hydrops by the carrier, balances the concentration of the anti-inflammatory drugs released by the carrier, further ensures the effect of removing the inflammatory factors in the joint cavity hydrops by the carrier, can be finally metabolized and absorbed by a human body, is high in safety, and can release the anti-inflammatory drugs due to the fact that the spherical outer wrapping layer formed by the phospholipid is prepared from the nanoscale anti-inflammatory drug particles;
therefore, the carrier for removing the inflammatory factors in the joint cavity hydrops and releasing the anti-inflammatory drugs can be metabolized and absorbed by a human body, not only can effectively remove the inflammatory factors in the joint cavity of the human body, but also can be released as the carrier to slowly release the anti-inflammatory drugs, finally achieves the purposes of removing the inflammatory factors in the joint cavity and controlling local inflammation so as to achieve the purpose of controlling the state of an illness, and has no side effect.
The parts not involved in the present invention are the same as or can be implemented by the prior art. The present embodiment is only for explaining the present invention, and it is not limited to the present invention, and those skilled in the art can make modifications of the present embodiment without inventive contribution as needed after reading the present specification, but all of them are protected by patent law within the scope of the claims of the present invention.
Claims (10)
1. A carrier for removing inflammatory factors from joint cavity fluid and releasing anti-inflammatory drugs, comprising:
the main part structure, the main part structure includes spherical outer parcel layer (1) and central spheroid (2), evenly be equipped with a plurality of through-holes (3) on spherical outer parcel layer (1), central spheroid (2) parcel is in the inside of spherical outer parcel layer (1).
2. The vehicle according to claim 1, wherein the vehicle is for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity effusion, and is characterized in that: the spherical outer wrapping layer (1) is formed by a membrane made of phospholipid.
3. The vehicle according to claim 1, wherein the vehicle is for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity effusion, and is characterized in that: the thickness of the spherical outer wrapping layer (1) is 50-100 um.
4. The vehicle according to claim 1, wherein the vehicle is for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity effusion, and is characterized in that: the through holes (3) are all round through holes.
5. The vehicle according to claim 4, wherein the vehicle is for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity effusion, and the vehicle comprises: a plurality of the apertures of the through holes (3) are all 30um-50 um.
6. The vehicle according to claim 1, wherein the vehicle is for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity effusion, and is characterized in that: the central sphere (2) is made of nano-scale anti-inflammatory drug particles.
7. The vehicle according to claim 6, wherein the vehicle is for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity effusion, and the vehicle comprises: the particle size of the anti-inflammatory drug particles is 50-80 nm.
8. The vehicle according to claim 1, wherein the vehicle is for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity effusion, and is characterized in that: the outer diameter of the spherical outer wrapping layer (1) is 300-500 mu m.
9. The vehicle according to claim 6, wherein the vehicle is for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity effusion, and the vehicle comprises: the anti-inflammatory drug comprises one or more of aspirin, acetaminophen, indomethacin, naproxen, naproxone, diclofenac, ibuprofen, nimesulide, rofecoxib and celecoxib.
10. The vehicle according to claim 2, wherein the vehicle is for removing inflammatory factors and releasing anti-inflammatory drugs from joint cavity effusion, and the vehicle comprises: the phospholipid is phosphoglyceride or sphingomyelin, and the phosphoglyceride is lecithin or cephalin or cardiolipin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110067765.7A CN112791063A (en) | 2021-01-19 | 2021-01-19 | Carrier for removing inflammatory factors in joint cavity hydrops and releasing anti-inflammatory drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110067765.7A CN112791063A (en) | 2021-01-19 | 2021-01-19 | Carrier for removing inflammatory factors in joint cavity hydrops and releasing anti-inflammatory drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112791063A true CN112791063A (en) | 2021-05-14 |
Family
ID=75810378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110067765.7A Pending CN112791063A (en) | 2021-01-19 | 2021-01-19 | Carrier for removing inflammatory factors in joint cavity hydrops and releasing anti-inflammatory drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112791063A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1852702A (en) * | 2003-07-31 | 2006-10-25 | 得克萨斯大学体系董事会 | Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same |
| CN105377238A (en) * | 2012-07-05 | 2016-03-02 | 台湾微脂体股份有限公司 | Methods of treating arthritis |
| CN106214641A (en) * | 2016-08-22 | 2016-12-14 | 沈阳鑫泰格尔医药科技开发有限公司 | A kind of liposome being applicable to water soluble drug and preparation method thereof |
-
2021
- 2021-01-19 CN CN202110067765.7A patent/CN112791063A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1852702A (en) * | 2003-07-31 | 2006-10-25 | 得克萨斯大学体系董事会 | Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same |
| CN105377238A (en) * | 2012-07-05 | 2016-03-02 | 台湾微脂体股份有限公司 | Methods of treating arthritis |
| CN106214641A (en) * | 2016-08-22 | 2016-12-14 | 沈阳鑫泰格尔医药科技开发有限公司 | A kind of liposome being applicable to water soluble drug and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davoudi et al. | Intestinal organoids containing poly (lactic‐co‐glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases | |
| Zhang et al. | Bioresponsive nanoparticles targeted to infectious microenvironments for sepsis management | |
| Song et al. | Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE−/−) mice | |
| Huang et al. | Intra-articular drug delivery systems for osteoarthritis therapy: Shifting from sustained release to enhancing penetration into cartilage | |
| Ward et al. | Paracetamol revisited: a review of the pharmacokinetics and pharmacodynamics | |
| Zink et al. | The long term myotoxic effects of bupivacaine and ropivacaine after continuous peripheral nerve blocks | |
| Hsu et al. | Intravesical drug delivery for dysfunctional bladder | |
| Xu et al. | Flexible MoS2‐embedded human serum albumin hollow nanocapsules with long circulation times and high targeting ability for efficient tumor ablation | |
| BRPI0518383A2 (en) | Chargeable polymeric particles for therapeutical and / or diagnostic applications and methods for preparing and using them | |
| Green-Sadan et al. | Glial cell line-derived neurotrophic factor-conjugated nanoparticles suppress acquisition of cocaine self-administration in rats | |
| Kim et al. | The inhibition of glioma growth in vitro and in vivo by a chitosan/ellagic acid composite biomaterial | |
| Berglin et al. | Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model | |
| WO1996019211A1 (en) | Liposome eye drops | |
| Clemente-Napimoga et al. | 15d-PGJ2-loaded in nanocapsules enhance the antinociceptive properties into rat temporomandibular hypernociception | |
| Solorio et al. | Effect of cargo properties on in situ forming implant behavior determined by noninvasive ultrasound imaging | |
| Shang et al. | Recent advances on transdermal delivery systems for the treatment of arthritic injuries: From classical treatment to nanomedicines | |
| JP2018502897A (en) | Injectable aggregates for joint and soft tissue pain | |
| CN112791063A (en) | Carrier for removing inflammatory factors in joint cavity hydrops and releasing anti-inflammatory drugs | |
| Jung et al. | A comparative pilot study of oral diacerein and locally treated diacerein-loaded nanoparticles in a model of osteoarthritis | |
| Lee et al. | Magnetically coated bioabsorbable stents for renormalization of arterial vessel walls after stent implantation | |
| KR102051143B1 (en) | Microrobot for hyperthermia and medical treatment material delivery | |
| Yang et al. | Multifunctional chitin-based hollow nerve conduit for peripheral nerve regeneration and neuroma inhibition | |
| Abbas et al. | PLA-coated Imwitor® 900 K-based herbal colloidal carriers as novel candidates for the intra-articular treatment of arthritis | |
| CN109106695B (en) | Preparation method of ibuprofen colon-targeted sustained-release microspheres | |
| Mei et al. | Polymer particles for the intra-articular delivery of drugs to treat osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210514 |